Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier

    Promotional slide CML 2022Register now for the 24th Annual John Goldman Conference on CML: Biology and Therapy

    October 21-23, 2022 - Mandelieu - La Napoule (France)
    Chairs: J. Cortes, T.P. Hughes, D.S. Krause

    Registration is now open
    Click here to register for the meeting


    Program Highlights:

    • Janet Rowley Prize award ceremony: recipient Oliver Hantschel (Marburg)
    • John Goldman Prize award ceremony: recipient Andreas Hochhaus (Jena)
    • iCMLf Prize award ceremony: Jan Geissler (Munich), Giora Sharf (Netanya)

    • Special Lecturers: 
      - Carlo Maley (Tempe)
      - Jyoti Nangalia (Cambridge)
      - Toni Ribas (Los Angeles)
      - Andreas Trumpp (Heidelberg)

    • Workshop for Non-Clinical Scientists #1
      Oncology/Hematology degraders - Degradation as a strategy against cancer
      Chairs: Oliver Hantschel (Marburg), Vignir Helgason (Glasgow)
      Speakers: George Burslem (Philadelphia), Stefan Knapp (Frankfurt), Charles Mullighan (Memphis)
    • Workshop for Non-Clinical Scientists #2
      3D Genomics and nuclear organization
      Chairs: Michael Deininger (Milwaukee), Jerry Radich (Seattle)
      Speakers: Steven Eacker (Seattle), Aristotelis Tsirigos (New York), Greg Wang (Chapel Hill)

    • Michele Baccarani Special Symposium
      Collaborative research in CML
      Chair: Giuseppe Saglio (Turin)
      Speakers: Rüdiger Hehlmann (Mannheim), Fausto Castagnetti (Bologna), Simona Soverini (Bologna), Susan Branford (Adelaide), François-Xavier Mahon (Bordeaux), Ehab Attalah (Milwaukee)

    • Debate #1
      Is ponatinib still the drug of choice for 3rd line therapy?
      Chair: Tim P. Hughes (Adelaide)
      Speakers: Jorge Cortes (Augusta), Delphine Réa (Paris)

    • Debate #2
      What is most important for CML persistence of the disease? Extrinsic factors or intrinsic factors?
      Chair: Ravi Bhatia (Birmingham)
      Speakers: Daniela Krause (Frankfurt), Mirle Schemionek-Reinders (Aachen)

    • Meet the Expert Sessions
      Understanding Biology of Leukemia / Practical implication of multimix appoaches in leukemia – Charles Mullighan (Memphis)
      Leukemic stem cell biology – Andreas Trumpp (Heidelberg)
      New frontiers in drug development in cancer – Stefann Knapp (Frankfurt)
      Management of advance stage CML – Maihri Copland (Glasgow)
      Challenging scenarios for TFR – Susanne Saussele (Mannheim)
      Management of TKI adverse event – Jeff Lipton (Toronto)

    The full program will be available soon.

    Presentation of data at this conference will not jeopardize acceptance of the same at the following ASH congress.